MoonLake Achieves Positive Consensus with FDA on BLA Submission for Sonelokimab
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 58 minutes ago
0mins
Should l Buy MLTX?
Source: Newsfilter
- FDA Meeting Outcome: On April 1, 2026, MoonLake reached a consensus with the FDA during its final pre-BLA meeting, confirming the acceptability of MIRA trial data to establish sonelokimab's effectiveness in HS, with BLA submission planned for the end of September 2026, marking a significant advancement in treatment options.
- Label Strategy Defined: The FDA agreed to include VELA-TEEN trial data in the label, covering patients aged 12 and above, with the label expected to feature a ~43% HiSCR75 response rate from the MIRA trial, showcasing the drug's outstanding performance in clinical trials and enhancing market competitiveness.
- Strong Financial Position: As of March 31, 2026, MoonLake reported $357.9 million in cash and short-term marketable debt securities, indicating sufficient capital to fund operations through the end of 2027, reflecting the company's financial stability for R&D and market initiatives.
- Upcoming Milestones: The company anticipates releasing 52-week data from the VELA-1 and VELA-2 trials within the next 12 months and primary endpoint results from the IZAR-1 trial in mid-2026, further advancing the clinical development of sonelokimab.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLTX
Wall Street analysts forecast MLTX stock price to rise
12 Analyst Rating
9 Buy
2 Hold
1 Sell
Moderate Buy
Current: 17.200
Low
5.00
Averages
24.10
High
45.00
Current: 17.200
Low
5.00
Averages
24.10
High
45.00
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MoonLake Achieves Positive Consensus with FDA on BLA Submission for Sonelokimab
- FDA Meeting Outcome: On April 1, 2026, MoonLake reached a consensus with the FDA during its final pre-BLA meeting, confirming the acceptability of MIRA trial data to establish sonelokimab's effectiveness in HS, with BLA submission planned for the end of September 2026, marking a significant advancement in treatment options.
- Label Strategy Defined: The FDA agreed to include VELA-TEEN trial data in the label, covering patients aged 12 and above, with the label expected to feature a ~43% HiSCR75 response rate from the MIRA trial, showcasing the drug's outstanding performance in clinical trials and enhancing market competitiveness.
- Strong Financial Position: As of March 31, 2026, MoonLake reported $357.9 million in cash and short-term marketable debt securities, indicating sufficient capital to fund operations through the end of 2027, reflecting the company's financial stability for R&D and market initiatives.
- Upcoming Milestones: The company anticipates releasing 52-week data from the VELA-1 and VELA-2 trials within the next 12 months and primary endpoint results from the IZAR-1 trial in mid-2026, further advancing the clinical development of sonelokimab.
See More
CEO Jorge Santos da Silva Sells 150,000 Shares of MoonLake Immunotherapeutics
- Transaction Scale Analysis: CEO Jorge Santos da Silva sold 150,000 shares of MoonLake Immunotherapeutics on April 10 and 13, 2026, through multiple open-market transactions valued at approximately $2.8 million, indicating a sale size above his average of 107,000 shares and marking his second-largest single sale since October 2023.
- Impact on Ownership Proportion: This transaction reduced Santos da Silva's direct ownership by 4.9%, leaving him with 2,924,893 shares, which indicates he still retains a significant stake, reflecting confidence in the company's future prospects.
- Market Reaction and Outlook: Despite MoonLake's stock price plummeting from a 52-week high of $62.75 due to disappointing clinical trial results for Sonelokimab, the recent FDA fast track designation may expedite market entry, providing a glimmer of hope for investors.
- Financial Overview: As of the end of 2025, MoonLake had $394 million in cash, with quarterly operating expenses around $65 million, suggesting the company has sufficient funds to sustain operations for a while, but investors must possess a high risk tolerance to navigate future uncertainties.
See More
CEO Jorge Santos da Silva Sells 150,000 Shares of MoonLake Immunotherapeutics
- Executive Sell-off: CEO Jorge Santos da Silva sold 150,000 shares of MoonLake Immunotherapeutics on April 10 and 13, 2026, for approximately $2.75 million, representing 4.9% of his holdings, which reduces his direct ownership to 2,924,893 shares, potentially signaling concerns about the company's future prospects.
- Market Performance Decline: MoonLake's stock has significantly dropped from a 52-week high of $62.75 reached last September, primarily due to disappointing clinical trial results for its Sonelokimab therapy; although the company recently received FDA fast track designation, its recovery hinges on the outcomes of ongoing trials.
- Financial Condition Analysis: As of the end of 2025, MoonLake had $394 million in cash with quarterly operating expenses around $65 million, providing sufficient runway for operations, but the lack of revenue until FDA approval poses a risk, necessitating investors to have a high-risk tolerance.
- Investment Caution: Despite MoonLake's potential in the biotech sector, analysts have noted that it was not included in the current list of top investment stocks, urging caution for investors considering entry, especially amid market volatility and uncertain clinical outcomes.
See More
BVF Partners Sells $62.96 Million in MoonLake Immunotherapeutics Shares
- Transaction Overview: On April 2, 2026, BVF Partners L.P. directly sold 3,750,000 shares of common stock for approximately $62.96 million, indicating ongoing interest in MoonLake Immunotherapeutics despite the sale.
- Historical Comparison: This transaction marks the largest direct sale reported by BVF in the SEC database, surpassing the previous sale of 2,000,000 shares, suggesting a strategic adjustment in their investment approach towards MoonLake.
- Holding Analysis: Post-transaction, BVF retains 15.9 million shares and an additional 25,667 shares via unexercised options, indicating a willingness to participate in future price appreciation, even after trimming its holdings.
- Investor Outlook: Although BVF reduced its stake by 19%, it still represents 8.76% of its total AUM, reflecting continued confidence in MoonLake's long-term growth potential, particularly with its proprietary Nanobody technology targeting significant unmet medical needs.
See More
BVF Sells 3.75 Million Shares of MoonLake Immunotherapeutics
- Sale Overview: On April 2, 2026, BVF Partners L.P. sold 3.75 million shares of MoonLake Immunotherapeutics for approximately $62.96 million, reducing its direct holdings to 1,039,238 shares, which represents a 78.30% decrease in ownership.
- Ownership Change: This transaction accounted for 78.30% of BVF's direct stake in MoonLake, indicating a strategic reduction in exposure to biotechnology investments rather than a complete exit, reflecting a cautious approach to market volatility.
- Company Strategy and Outlook: MoonLake focuses on leveraging its proprietary Nanobody technology to develop innovative therapies for inflammatory diseases, and despite BVF's sale, the company continues to advance its pipeline targeting dermatological and rheumatological conditions, suggesting potential for long-term growth.
- Market Reaction and Investment Advice: Although MoonLake's shares have rebounded sharply since the beginning of the year, the high volatility in the biotechnology sector necessitates caution from investors; BVF's sale appears more as a portfolio rebalancing move rather than a negative outlook on the company's future prospects.
See More
MoonLake's Clinical Trial Results Spark Interest
- Clinical Trial Results: MoonLake recently announced that in its late-stage trials, 62% of patients treated with sonelokimab achieved a 75% reduction in abscess and inflammatory nodule count, setting a new standard for long-term control of HS, surpassing existing FDA-approved drugs.
- Positive Market Reaction: Following the clinical data release, MoonLake's stock garnered significant retail interest on Stocktwits, with sentiment remaining in the 'extremely bullish' territory, indicating strong confidence in the company's future performance.
- Optimistic Analyst Ratings: According to Koyfin, 12 out of 16 analysts covering MLTX rated it 'Buy' or higher, with an average 12-month price target of $26.71, suggesting a potential upside of about 41%, reflecting market expectations for long-term growth.
- Acquisition Rumors Resurface: Despite Merck's failed attempt to acquire MoonLake for over $3 billion, optimism regarding potential future buyouts remains strong among investors, driven by interest in recent mergers in the biopharma sector, which could further boost the stock price.
See More
MoonLake Achieves Positive Consensus with FDA on BLA Submission for Sonelokimab
- FDA Meeting Outcome: On April 1, 2026, MoonLake reached a consensus with the FDA during its final pre-BLA meeting, confirming the acceptability of MIRA trial data to establish sonelokimab's effectiveness in HS, with BLA submission planned for the end of September 2026, marking a significant advancement in treatment options.
- Label Strategy Defined: The FDA agreed to include VELA-TEEN trial data in the label, covering patients aged 12 and above, with the label expected to feature a ~43% HiSCR75 response rate from the MIRA trial, showcasing the drug's outstanding performance in clinical trials and enhancing market competitiveness.
- Strong Financial Position: As of March 31, 2026, MoonLake reported $357.9 million in cash and short-term marketable debt securities, indicating sufficient capital to fund operations through the end of 2027, reflecting the company's financial stability for R&D and market initiatives.
- Upcoming Milestones: The company anticipates releasing 52-week data from the VELA-1 and VELA-2 trials within the next 12 months and primary endpoint results from the IZAR-1 trial in mid-2026, further advancing the clinical development of sonelokimab.
See More
CEO Jorge Santos da Silva Sells 150,000 Shares of MoonLake Immunotherapeutics
- Transaction Scale Analysis: CEO Jorge Santos da Silva sold 150,000 shares of MoonLake Immunotherapeutics on April 10 and 13, 2026, through multiple open-market transactions valued at approximately $2.8 million, indicating a sale size above his average of 107,000 shares and marking his second-largest single sale since October 2023.
- Impact on Ownership Proportion: This transaction reduced Santos da Silva's direct ownership by 4.9%, leaving him with 2,924,893 shares, which indicates he still retains a significant stake, reflecting confidence in the company's future prospects.
- Market Reaction and Outlook: Despite MoonLake's stock price plummeting from a 52-week high of $62.75 due to disappointing clinical trial results for Sonelokimab, the recent FDA fast track designation may expedite market entry, providing a glimmer of hope for investors.
- Financial Overview: As of the end of 2025, MoonLake had $394 million in cash, with quarterly operating expenses around $65 million, suggesting the company has sufficient funds to sustain operations for a while, but investors must possess a high risk tolerance to navigate future uncertainties.
See More
CEO Jorge Santos da Silva Sells 150,000 Shares of MoonLake Immunotherapeutics
- Executive Sell-off: CEO Jorge Santos da Silva sold 150,000 shares of MoonLake Immunotherapeutics on April 10 and 13, 2026, for approximately $2.75 million, representing 4.9% of his holdings, which reduces his direct ownership to 2,924,893 shares, potentially signaling concerns about the company's future prospects.
- Market Performance Decline: MoonLake's stock has significantly dropped from a 52-week high of $62.75 reached last September, primarily due to disappointing clinical trial results for its Sonelokimab therapy; although the company recently received FDA fast track designation, its recovery hinges on the outcomes of ongoing trials.
- Financial Condition Analysis: As of the end of 2025, MoonLake had $394 million in cash with quarterly operating expenses around $65 million, providing sufficient runway for operations, but the lack of revenue until FDA approval poses a risk, necessitating investors to have a high-risk tolerance.
- Investment Caution: Despite MoonLake's potential in the biotech sector, analysts have noted that it was not included in the current list of top investment stocks, urging caution for investors considering entry, especially amid market volatility and uncertain clinical outcomes.
See More
BVF Partners Sells $62.96 Million in MoonLake Immunotherapeutics Shares
- Transaction Overview: On April 2, 2026, BVF Partners L.P. directly sold 3,750,000 shares of common stock for approximately $62.96 million, indicating ongoing interest in MoonLake Immunotherapeutics despite the sale.
- Historical Comparison: This transaction marks the largest direct sale reported by BVF in the SEC database, surpassing the previous sale of 2,000,000 shares, suggesting a strategic adjustment in their investment approach towards MoonLake.
- Holding Analysis: Post-transaction, BVF retains 15.9 million shares and an additional 25,667 shares via unexercised options, indicating a willingness to participate in future price appreciation, even after trimming its holdings.
- Investor Outlook: Although BVF reduced its stake by 19%, it still represents 8.76% of its total AUM, reflecting continued confidence in MoonLake's long-term growth potential, particularly with its proprietary Nanobody technology targeting significant unmet medical needs.
See More
BVF Sells 3.75 Million Shares of MoonLake Immunotherapeutics
- Sale Overview: On April 2, 2026, BVF Partners L.P. sold 3.75 million shares of MoonLake Immunotherapeutics for approximately $62.96 million, reducing its direct holdings to 1,039,238 shares, which represents a 78.30% decrease in ownership.
- Ownership Change: This transaction accounted for 78.30% of BVF's direct stake in MoonLake, indicating a strategic reduction in exposure to biotechnology investments rather than a complete exit, reflecting a cautious approach to market volatility.
- Company Strategy and Outlook: MoonLake focuses on leveraging its proprietary Nanobody technology to develop innovative therapies for inflammatory diseases, and despite BVF's sale, the company continues to advance its pipeline targeting dermatological and rheumatological conditions, suggesting potential for long-term growth.
- Market Reaction and Investment Advice: Although MoonLake's shares have rebounded sharply since the beginning of the year, the high volatility in the biotechnology sector necessitates caution from investors; BVF's sale appears more as a portfolio rebalancing move rather than a negative outlook on the company's future prospects.
See More
MoonLake's Clinical Trial Results Spark Interest
- Clinical Trial Results: MoonLake recently announced that in its late-stage trials, 62% of patients treated with sonelokimab achieved a 75% reduction in abscess and inflammatory nodule count, setting a new standard for long-term control of HS, surpassing existing FDA-approved drugs.
- Positive Market Reaction: Following the clinical data release, MoonLake's stock garnered significant retail interest on Stocktwits, with sentiment remaining in the 'extremely bullish' territory, indicating strong confidence in the company's future performance.
- Optimistic Analyst Ratings: According to Koyfin, 12 out of 16 analysts covering MLTX rated it 'Buy' or higher, with an average 12-month price target of $26.71, suggesting a potential upside of about 41%, reflecting market expectations for long-term growth.
- Acquisition Rumors Resurface: Despite Merck's failed attempt to acquire MoonLake for over $3 billion, optimism regarding potential future buyouts remains strong among investors, driven by interest in recent mergers in the biopharma sector, which could further boost the stock price.
See More
